-
Expand your territory again! Alnylam RNAi therapy is approved for marketing in Europe
Time of Update: 2022-10-01
September 22, 2022 / Alnylam, a leading company in RNAi therapies, recently announced that the European Commission (EC) has approved the marketing authorization of its RNAi therapy AMVUTTRA ® (vutrisiran) for the treatment of stage 1 and 2 polyneuropathy in adults with hereditary transthyroxinin-mediated (hATTR) amyloidosis。 This is the first RNAi therapy to reverse neuropathy with just subcutaneous administration every 3 months.
-
How NDT can quickly conduct adequate corrosion assessment of gas pipelines
Time of Update: 2022-08-15
Welcome new and old customers to communicate with our application technology experts to discuss industry prospects and application practices!From July 28th to July 30th, 2022 From July 28th to July 30th, 2022 From July 28th to July 30th, 2022 , CREAFORM China will appear at the 22nd China International Petroleum and Petrochemical Technology and Equipment Exhibition, we sincerely invite you to visit!
-
All my country's oil and gas main pipeline networks are connected to the grid
Time of Update: 2021-09-24
(referred to as National Pipe Network Group) formally took over the equity of Beijing Natural Gas Pipeline Co.
According to the equity transfer agreement signed by the two parties on March 31, the State Pipeline Network Group acquired 60% of the Beijing Pipeline Company under PetroChina Kunlun Energy and 75% of the shares of Dalian LNG Company.
-
AffaMed Therapeutics announces the completion of more than $170 million in Series B financing
Time of Update: 2021-07-12
AffaMed Therapeutics, a clinical-stage innovative biopharmaceutical company dedicated to meeting the needs of patients with global ophthalmology, neurological and psychiatric diseases, announced the completion of more than $170 million in Series B financing .
-
Pfizer pulled out and stopped seeking to buy Shishi Shiguibo
Time of Update: 2021-02-21
The industry has long been rumoured that BMY, the pharmaceutical giant, is going to be acquired, and if that's true, there's one company that has the power but won't make a bid, and that's Pfizer (PFE
-
Biopharmaceutical pattern changes! Industry innovation becomes more and more scattered
Time of Update: 2019-03-19
In the global pharmaceutical industry, there are usually 50 to 120 acquisitions a year, through which the two merged companies become larger entities (see Figure 1) Therefore, we can reasonably assume
-
JPM report: what will happen to biomedical companies in 2018
Time of Update: 2018-01-12
Source: Wuxi apptec 2018-01-12 today, J.P Morgan Healthcare Conference is coming to an end During the conference, many large pharmaceutical enterprises and start-ups summarized their work in 2017, and
-
Another multinational giant cardiovascular medicine failed! Failure history of watching hot targets
Time of Update: 2015-10-29
Source: 15 days before October 29, 2015 (October 12), Lilly announced to stop the research of CETP inhibitor heart disease drug evacetrapib Fifteen days later (October 27), another multinational giant announced that one of its drugs had failed in a large phase III clinical trial of acute coronary syndrome This time, losmapimod, a p38MAP kinase inhibitor of GSK, was used It's also cardiovascular medicine!
-
Main application fields of three precision valve products in 10 categories
Time of Update: 2014-09-18
With the various needs of modern life, then the production of these important products of spare parts are endless Below we list 10 main application fields of our company's Sanjing valve products 1 Val
